{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:55:35Z","timestamp":1791248135516,"version":"4.1.0"},"reference-count":46,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2008,6,28]],"date-time":"2008-06-28T00:00:00Z","timestamp":1214611200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2008,10]]},"abstract":"<jats:sec><jats:label\/><jats:p><jats:bold>WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT<\/jats:bold><\/jats:p><jats:p>\u2022\u20036\u2010Mercaptopurine (6\u2010MP) and azathioprine (AZA) are both inactive prodrugs that require intracellular activation into the active 6\u2010thioguanine nucleotides (6\u2010TGNs).<\/jats:p><jats:p>\u2022\u2003This metabolic process undergoes three different competitive pathways that are catalysed by three different enzymes; xanthine oxidase (XO), thiopurine methyltransferase (TPMT) and inosine triphosphatase (ITPA), all of which exhibit genetic polymorphisms.<\/jats:p><jats:p>\u2022\u2003Although the impact of genetic variation in the<jats:italic>TPMT<\/jats:italic>gene on treatment outcome and toxicity has been demonstrated, the role of other polymorphisms remains less well known.<\/jats:p><jats:p><jats:bold>WHAT THIS STUDY ADDS<\/jats:bold><\/jats:p><jats:p>\u2022\u2003New information on the allelic variation of these three enzymes (XO, TPMT and ITPA) and their influence on 6\u2010MP\/AZA metabolism and toxicity.<\/jats:p><jats:p>\u2022\u2003Confirmation of the association of<jats:italic>TPMT<\/jats:italic>polymorphism with haematological toxicity.<\/jats:p><jats:p>\u2022\u2003Identified potential genetic characteristics that may contribute to higher risk of adverse events (such as<jats:italic>ITPA IVS2<\/jats:italic>+<jats:italic>21A<\/jats:italic>\u2192<jats:italic>C<\/jats:italic>mutation).<\/jats:p><\/jats:sec><jats:sec><jats:title>AIMS<\/jats:title><jats:p>To examine the allelic variation of three enzymes involved in 6\u2010mercaptopurine\/azathioprine (6\u2010MP\/AZA) metabolism and evaluate the influence of these polymorphisms on toxicity, haematological parameters and metabolite levels in patients with acute lymphoblastic leukaemia (ALL) or inflammatory bowel disease (IBD).<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Clinical data and blood samples were collected from 19 ALL paediatric patients and 35 IBD patients who were receiving 6\u2010MP\/AZA therapy. All patients were screened for seven genetic polymorphisms in three enzymes involved in mercaptopurine metabolism [<jats:italic>xanthine oxidase<\/jats:italic>,<jats:italic>inosine triphosphatase<\/jats:italic>(<jats:italic>C94<\/jats:italic>\u2192<jats:italic>A<\/jats:italic>and<jats:italic>IVS2<\/jats:italic>+<jats:italic>21A<\/jats:italic>\u2192<jats:italic>C<\/jats:italic>) and<jats:italic>thiopurine methyltransferase<\/jats:italic>]. Erythrocyte and plasma metabolite concentrations were also determined. The associations between the various genotypes and myelotoxicity, haematological parameters and metabolite concentrations were determined.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p><jats:italic>Thiopurine methyltransferase<\/jats:italic>variant alleles were associated with a preferential metabolism away from 6\u2010methylmercaptopurine nucleotides (<jats:italic>P<\/jats:italic>\u2003=\u20030.008 in ALL patients,<jats:italic>P<\/jats:italic>\u2003=\u20030.038 in IBD patients) favouring 6\u2010thioguanine nucleotides (6\u2010TGNs) (<jats:italic>P<\/jats:italic>\u2003=\u20030.021 in ALL patients). Interestingly, carriers of<jats:italic>inosine triphosphatase IVS2<\/jats:italic>+<jats:italic>21A<\/jats:italic>\u2192<jats:italic>C<\/jats:italic>variants among ALL and IBD patients had significantly higher concentrations of the active cytotoxic metabolites, 6\u2010TGNs (<jats:italic>P<\/jats:italic>\u2003=\u20030.008 in ALL patients,<jats:italic>P<\/jats:italic>\u2003=\u20030.047 in IBD patients). The study confirmed the association of<jats:italic>thiopurine methyltransferase<\/jats:italic>heterozygosity with leucopenia and neutropenia in ALL patients and reported a significant association between<jats:italic>inosine triphosphatase IVS2<\/jats:italic>+<jats:italic>21A<\/jats:italic>\u2192<jats:italic>C<\/jats:italic>variants with thrombocytopenia (<jats:italic>P<\/jats:italic>\u2003=\u20030.012).<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>Pharmacogenetic polymorphisms in the 6\u2010MP pathway may help identify patients at risk for associated toxicities and may serve as a guide for dose individualization.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1365-2125.2008.03248.x","type":"journal-article","created":{"date-parts":[[2008,6,20]],"date-time":"2008-06-20T11:35:35Z","timestamp":1213961735000},"page":"517-528","source":"Crossref","is-referenced-by-count":85,"title":["Pharmacogenomic studies of the anticancer and immunosuppressive thiopurines mercaptopurine and azathioprine"],"prefix":"10.1111","volume":"66","author":[{"given":"Ahmed F.","family":"Hawwa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff S.","family":"Millership","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul S.","family":"Collier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen","family":"Vandenbroeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sid","family":"Dempsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Cairns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Rodgers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James C.","family":"McElnay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,9,11]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01416.x"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V93.9.2817"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.50.4.485"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/00054725-200301000-00006"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1053\/bega.2002.0346"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02220605"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(94)90515-0"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2006.02980.x"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.fpc.0000114745.08559.db"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)91745-V"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.2.345"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/91.23.1983"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.04932.x"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1991.205"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1999.00884.x"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-200403000-00006"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00439-002-0798-z"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9120(00)00175-2"},{"key":"e_1_2_6_20_2","first-page":"601","article-title":"Thiopurine pharmacogenetics: clinical and molecular studies of thiopurine methyltransferase","volume":"29","author":"Weinshilboum R.","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2001.00366.x"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-200404000-00024"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2005.03832.x"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.2005.00904.x"},{"issue":"1","key":"e_1_2_6_25_2","first-page":"S30","article-title":"Clinical use and practical application of TPMT enzyme and 6\u2010mercaptopurine metabolite monitoring in IBD","volume":"3","author":"Seidman EG.","year":"2003","journal-title":"Rev Gastroenterol Disord"},{"key":"e_1_2_6_26_2","first-page":"150","article-title":"Pharmacogenomics of azathioprine and 6\u2010mercaptopurine in gastroenterologic therapy","volume":"3","author":"Baker DE.","year":"2003","journal-title":"Rev Gastroenterol Disord"},{"issue":"1","key":"e_1_2_6_27_2","first-page":"A3","article-title":"Improved HPLC methodology for the determination of mercaptopurine and its metabolites in plasma and red blood cells","volume":"58","author":"Hawwa AF","year":"2006","journal-title":"J Pharm Pharmacol"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.300.6719.230"},{"key":"e_1_2_6_29_2","first-page":"1202","article-title":"Basic biochemical effects and mechanism of action of 6\u2010thioguanine","volume":"23","author":"Lepage GA.","year":"1963","journal-title":"Cancer Res"},{"key":"e_1_2_6_30_2","first-page":"1670","article-title":"Quantitation of 6\u2010thioguanine residues in peripheral blood leukocyte DNA obtained from patients receiving 6\u2010mercaptopurine\u2010based maintenance therapy","volume":"55","author":"Warren DJ","year":"1995","journal-title":"Cancer Res"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-126-8-199704150-00003"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1086\/301941"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-199302000-00010"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198304283081705"},{"key":"e_1_2_6_35_2","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S0026-895X(25)08754-1","article-title":"Methylation of mercaptopurine, thioguanine, and their nucleotide metabolites by heterologously expressed human thiopurine S\u2010methyltransferase","volume":"47","author":"Krynetski EY","year":"1995","journal-title":"Mol Pharmacol"},{"key":"e_1_2_6_36_2","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0021-9258(17)43612-X","article-title":"Inhibition of mammalian xanthine oxidase by folate compounds and amethopterin","volume":"259","author":"Lewis AS","year":"1984","journal-title":"J Biol Chem"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)93168-Z"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V85.7.1897.bloodjournal8571897"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-129-9-199811010-00007"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1209372"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.2165\/00129785-200303060-00002"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.51.2.143"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-200406000-00016"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1081\/NCN-200027639"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2004.055947"},{"key":"e_1_2_6_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0399-8320(05)82219-5"},{"key":"e_1_2_6_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(00)70354-4"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2125.2008.03248.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2125.2008.03248.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T19:16:21Z","timestamp":1738264581000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2125.2008.03248.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9,11]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,10]]}},"alternative-id":["10.1111\/j.1365-2125.2008.03248.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2125.2008.03248.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,9,11]]}}}